| Literature DB >> 383125 |
T J McElwain, D W Hedley, G Burton, H M Clink, M Y Gordon, M Jarman, C A Juttner, J L Millar, R A Milsted, G Prentice, I E Smith, D Spence, M Woods.
Abstract
In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was a safe time to administer non-cryopreserved marrow. Four patients received lower doses of i.v. melphalan without autologous marrow. In the group receiving autologous marrow the time for recovery of peripheral-blood granulocytes to 800/mm2 or greater was significantly less (P = 0.01) than in those not receiving marrow. In 7 patients the tumour showed evidence of response to the drug and there was 1 complete remission. This treatment deserves investigation in patients with tumours more sensitive to drugs than melanoma.Entities:
Mesh：
Substances：
Year: 1979 PMID： 383125 PMCID： PMC2009972 DOI： 10.1038/bjc.1979.142
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640